Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Celgene Acquiring Juno Therapeutics for $9 Billion

January 22nd 2018

Celgene has announced plans to acquire Juno Therapeutics, maker of the CAR T-cell therapy lisocabtagene maraleucel (JCAR017), for $87 per share, totaling approximately $9 billion.

Promising Immunotherapy Approaches in AML

January 19th 2018

Promising Targeted Approaches in AML

January 19th 2018

Defining the Challenges of FLT3 Inhibition in AML

January 19th 2018

Emerging FLT3 Inhibitors in AML

January 19th 2018

Second-Generation FLT3 Inhibitors in AML: Quizartinib

January 19th 2018

MRD's Potential Role in Treating Acute Myeloid Leukemia

January 19th 2018

Treating CD33-Positive AML With Gemtuzumab Ozogamicin

January 19th 2018

AML: Identifying Practical Concerns With Enasidenib

January 19th 2018

Enasidenib's Role in IDH-Mutant Acute Myeloid Leukemia

January 19th 2018

Considering Midostaurin for Acute Myeloid Leukemia

January 19th 2018

RATIFY Trial: Midostaurin's Role in Treating AML

January 19th 2018

Considerations for CPX-351 in Acute Myeloid Leukemia

January 19th 2018

Promise of Recently Approved Agents for AML: CPX-351

January 19th 2018

Debating an Algorithm for Molecular Testing in AML

January 19th 2018

Recommended Molecular Testing in Acute Myeloid Leukemia

January 19th 2018

The Microenvironment and Epigenetics in AML

January 19th 2018

Acute Myeloid Leukemia: Understanding Biologic Drivers

January 19th 2018

Expert Highlights Advances in Cutaneous T-Cell Lymphoma

January 19th 2018

Wei Z. Ai, MD, discusses the impact of brentuximab vedotin, as well as the potential with mogamulizumab in cutaneous T-cell lymphoma.

Dr. Mannis Talks About Emerging Treatments for Acute Myeloid Leukemia

January 19th 2018

Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses new methods of treatment for acute myeloid leukemia.